BOULDER, CO – Encision Inc. (OTCBB:ECIA), a medical device company, announced the results of its Annual Meeting of Stockholders held on Thursday. The company, which specializes in surgical and medical instruments, confirmed the election of four directors and the ratification of its independent registered accounting firm.
At the Annual Meeting, shareholders voted on two key proposals. The first proposal involved the election of directors, with each director serving until the 2025 annual meeting or until a successor is elected and qualified. The elected directors are Robert H. Fries, Vern D. Kornelsen, Patrick W. Pace, and Gregory J. Trudel.
The votes for these individuals ranged from 6,020,428 to 7,055,834, with withheld votes ranging from 82,366 to 1,117,772 and broker non-votes totaling 1,883,560 for each nominee.
The second proposal was the ratification of Green Growth CPAs as the company's independent registered accounting firm. This proposal received significant support, with 8,691,669 votes for, 250,019 against, and 80,072 abstentions, and no broker non-votes.
Encision, previously known as Electroscope Inc. until its name change on May 2, 1996, is incorporated in Colorado and operates with a fiscal year ending on March 31. The company's business address and principal executive offices are located at 6797 Winchester Circle, Boulder, Colorado 80301.
InvestingPro Insights
As Encision Inc. (OTCBB:ECIA) continues its journey in the healthcare sector, it's important for investors to monitor the company's financial health and market performance. According to the latest InvestingPro data, Encision has a market capitalization of approximately $3.5 million. Despite a challenging period, with revenue showing a decline of over 10% in the last twelve months as of Q4 2024, the company maintains a strong gross profit margin of 47.62%. This indicates that while Encision's sales are down, it still retains a relatively high percentage of revenue after accounting for the cost of goods sold.
InvestingPro Tips reveal that Encision has not been profitable over the last twelve months and has experienced a significant price drop of 42% over the last three months. The stock has also fared poorly over the last month, with a total price return of -30.95%. These metrics suggest that investors should exercise caution and closely follow the company's performance. Additionally, the company does not pay dividends, which could be a consideration for income-focused investors.
For those seeking a deeper analysis, InvestingPro provides additional tips on Encision, offering a comprehensive view of potential investment strategies. To explore these insights and to stay informed about Encision's financial performance, interested parties can visit https://www.investing.com/pro/ECIA.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.